<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between May 1987 and January 1991, 1354 patients, 1-21 years old, with standard or poor prognosis B-lineage <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> were treated on the Pediatric <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group Study 8602 </plain></SENT>
<SENT sid="1" pm="."><plain>One thousand three hundred and twenty-three patients entered remission and 1051 patients were randomized on day 43 to an intensification regimen containing L-asparaginase and intermediate-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (regimen B) or <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and intermediate dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (regimen C) </plain></SENT>
<SENT sid="2" pm="."><plain>After completion of intensification at week 25, <z:hpo ids='HP_0000001'>all</z:hpo> patients received the same maintenance therapy until 3 years from diagnosis </plain></SENT>
<SENT sid="3" pm="."><plain>Overall 5-year continuous complete remission (CCR) for regimen B was 72+/-2% (s.e.) and for regimen C, 73+/-2% (P = 0.72 by log-rank analysis) </plain></SENT>
<SENT sid="4" pm="."><plain>Significant differences between treatments for CCR, testicular, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapses overall or with regard to phenotype (pre-B vs early pre-B), gender, or race were not detected </plain></SENT>
<SENT sid="5" pm="."><plain>During intensification, regimen C had significantly more <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (P = 0.05) and days spent in the hospital (P &lt; 0.001) compared with regimen B, while regimen B had significantly more allergic reactions (P &lt; 0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>No significant differences in CCR were noted between patients with pre-B and early <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre-B ALL</z:e> (P = 0.22 stratified by risk group and treatment) </plain></SENT>
<SENT sid="7" pm="."><plain>This study was unable to detect statistical difference between asparaginase (regimen B) and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (regimen C) during the intensification phase of therapy in children with B-lineage <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
</text></document>